帕瓦停(pravastutin)为3-羟-3-甲戊二酰辅酶A(HMG COA)还原酶抑制剂,能降低高脂蛋白血症(HLP)病人的胆固醇,且对血糖及胰岛素代谢有影响。本文作者通过观察HLP病人应用帕瓦停治疗前后血糖,胰岛素及脂蛋白等指标的变化,说明了帕瓦停治疗HLP病人时的适应证、治疗意义及可能有的副作用。 方法 根据胆固醇浓度,HLP可分为 Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG COA) reductase inhibitor, reduces cholesterol in patients with hyperlipoproteinemia (HLP) and has effects on blood glucose and insulin metabolism . By observing the changes of blood glucose, insulin and lipoprotein in HLP patients before and after the application of Parvacide, the authors described the indications, the therapeutic significance and the possible side effects of Parvacide in the treatment of HLP. Methods According to cholesterol concentration, HLP can be divided into